Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease

Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.

Material and methods. The study included 49 patients (aged of 61.53±1.14 years; 31 [63.3%] men) receiving alirocumab who did not reach the target low density lipoprotein cholesterol (LDL-C) concentrations despite the ongoing optimal lipid-lowering therapy. In all patients, the initial level of lipids was evaluated, as well as their parameters after subsequent alirocumab injections.

Results. LDL-C serum level significantly decreased after the first injection compared to the initial level from 2.92±0.22 to 1.65±0.19 mmol/L (p<0.001; Δ45.31±3.61%) and down to 1.74±0.17 mmol/L for the entire study period (p<0.001; Δ41.52±2.69%). The change in LDL-C level between injections did not show statistically significant differences (p=0.141). A direct strong statistically significant correlation between the LDL-C level after the first injection and its average values for the entire observation period was found (r=0.958, p<0.001).

Conclusion. The results of the study indicate that the PCSK9 inhibitor, alirocumab, in patients who need secondary prevention of CVD shows a significant additional decrease in the concentration of LDL-C after the first injection. At the same time, approximately half of the patients were able to achieve the recommended levels of LDL-C. The persistence of the achieved low LDL-C levels over time demonstrated that the average concentration of LDL-C during the observation corresponded to the values after the first injection. This finding shows that there is no need for constant monitoring of lipid metabolism parameters when prescribing such therapy.

1. World Health Organization. The Global Burden of Disease. Geneva: World Health Organization; 2008.

2. Averin E.E., Nikitin A.E., Nikitin I.G., Sozykin A.V. New European Guidelines for Hypertension: A Focus on Combination Therapy. Meditsinskiy Alfavit. 2018;4(37):5-11 (In Russ.)

3. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. DOI:10.1016/j.jacc.2013.11.002.

4. Piepoli M.F., Hoes A.W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):231581. DOI:10.1093/eurheartj/ehw106.

5. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122 (In Russ.) DOI:10.15829/1560-4071-20186-7-122.

6. Leal J., Luengo-Fernandez R., Gray A., et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27(13):1610-9. DOI:10.1093/eurheartj/ehi733.

7. Gordienko A.V., Nikitin A.E., Yakovlev V.V. Features of disorders of lipid-cholesterol metabolism at young and middle-aged men with primary recurrent myocardial infarction. Vestnik Rossiyskoy Voennomeditsinskoy Akademii. 2009;3(27):7-10 (In Russ.)

8. Averin E.E. Rehabilitation of cardiac patients: Socio-legal aspects. Vrach. 2010;7:19-22 (In Russ.)

9. Averin E.E. Social rehabilitation opportunities. V Mire Nauchnih Otkritiy. 2010;3-4(9):130 (In Russ.)

10. Averin E.E. Socially significant differences in the rehabilitation of cardiac surgery centers. V Mire Nauchnih Otkritiy. 2010;3-4(9):131 (In Russ.)

11. Averin E.E. Cardiac Surgery: Psychological, Social and Legal Aspects of Rehabilitation. CardioSomatika. 2011;S1:3-4 (In Russ.)

12. Averin E.E., Lopatin Y.M., Delaru V.V. Rehabilitation of cardiosurgical patients in Russia: medical, social, psychological and legal aspects. Heart Failure Journal. 2012;13(1):40-5 (In Russ.)

13. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. DOI:10.1093/eurheartj/ehw272.

14. Aronov D.M., Arabidze G. G., Akhmedzhanov N.M., et al. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, 2017 [cited by Dec 20, 2019]. Available from: https://scardio.ru/content/Guidelines/rek_lipid_2012.pdf (In Russ.)

15. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. DOI:10.1093/eurheartj/ehz455.

16. Susekov A.V., Nikitin A.E. The Past and Near Future of Statin Therapy in Russia. Lechebnoye Delo. 2018;3:30-7 (In Russ.)

17. Averin E.E., Nikitin A.E., Nikitin I.G., et al. The optimal choice of statin for patients with high and very high cardiovascular risk and impaired carbohydrate metabolism. Meditsinskiy Alfavit. 2018;3(32):511 (In Russ.)

18. Mullard A. Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat Rev Drug Discov. 2012;11(11):817-9. DOI:10.1038/nrd3879.

19. Whayne T.F. Jr. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. Am J Cardiovasc Drugs. 2016;16(2):83-92. DOI:10.1007/s40256-015-0150-3.

20. Rozhkov D.E., Averin E.E., Nikitin A.E., et al. Features of actual state of lipid metabolism in patients after suffering cardiovascular events. Meditsinskiy Alfavit. 2018;32(3):19-28 (In Russ.)

21. Nikitin A.E., Nikitin I.G., Dedov E.I., et al. Ways to optimize treatment of patients in multidisciplinary hospital: focus on state of lipid metabolism. Meditsinskiy Alfavit. 2018;32(3):29-39 (In Russ.)

22. Bovtyushko P.V., Shmorgun T.S., Filippov A.E., et al. The effect of preventive measures on endothelial function in patients with arterial hypertension. Vestnik Rossiyskoy Voenno-meditsinskoy Akademii. 2009;40(28):148-51 (In Russ.)

23. Alferov S.P., Svistov A.S., Nikitin A.E., et al. The relationship between myocardial perfusion indicators, the course of heart failure, and the functional class of angina pectoris in patients after acute coronary syndrome without persistent ST segment elevation. Vestnik Rossiyskoy Voenno-meditsinskoy Akademii. 2009;1(25):14-8 (In Russ.)

24. Shevchenko Y.L., Tyrenko V.V., Nikitin A.E., et al. A study of adrenergic innervation of the myocardium in patients with cardiac syndrome X. Clinical Medicine. 2001;10:14 (In Russ.)

25. Kotseva K., Wood D., DeBacker G., et al.; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-37. DOI:10.1097/HJR.0b013e3283294b1d.

26. Banegas J.R., Lopez-Garcia E., Dallongeville J., et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32(17):2143-52. DOI:10.1093/eurheartj/ehr080.

27. Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273-93. DOI:10.1146/annurev-pharmtox-011613-140025.